Role of Stem Cell Transplantation

Hematology/Oncology Clinics of North America

Volumn 21, Issue 6, 2007, Pages 1157-1174

  Harousseau, Jean Luc ^a  

^a HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; LENALIDOMIDE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PAMIDRONIC ACID; PREDNISONE; THALIDOMIDE; THYMOCYTE ANTIBODY; VINCRISTINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; GRAFT VERSUS HOST REACTION; HUMAN; INTERMETHOD COMPARISON; MAINTENANCE THERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 35748965609     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2007.08.001     Document Type: Review

References (90)

1. Osserman E.F., Dire L.B., Dire J., et al. Identical twin marrow transplantation in multiple myeloma. Acta Haematol 68 (1982) 215-223
2. Barlogie B., Alexanian R., Dicke K.A., et al. High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 70 (1987) 869-872
3. Attal M., Harousseau J.L., Stoppa A.M., et al., for the Intergroupe Français du Myélome. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335 (1996) 91-97
4. Child J.A., Morgan G.J., Davies F.E., et al., Medical research Council Adult Leukemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348 (2003) 1875-1883
5. Fermand J.P., Ravaud P., Chevret S., et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized trial. Blood 92 (1998) 3131-3136
6. Fermand J.P., Katsahian S., Divine M., et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Groupe Myelome-Autogreffe. J Clin Oncol 23 (2005) 9227-9233
7. Blade J., Samson D., Reece D., et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 102 (1998) 1115-1123
8. Durie B.G., Harousseau J.L., Miguel J.S., et al. International uniform response criteria for multiple myeloma. Leukemia 20 (2006) 1467-1473
9. Blade J., Rosinol L., Sureda A., et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 106 (2005) 3755-3759
10. Barlogie B., Kyle R.A., Anderson K.C., et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 24 (2006) 929-936
11. Alexanian R., Dimopoulos M.A., Hester J., et al. Early myeloablative therapy for multiple myeloma. Blood 84 (1994) 4278-4282
12. Kumar S., Lacy M.Q., Dispenzieri A., et al. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant 34 (2004) 161-167
13. Harousseau J.L., Milpied N., Laporte J.P., et al. Double-intensive therapy in high-risk multiple myeloma. Blood 79 (1992) 3131-3136
14. Barlogie B., Jagannath S., Desikan K.R., et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 93 (1999) 55-65
15. Attal M., Harousseau J.L., Facon T., et al. Intergroupe Francophone du Myélome: single versus double autologous stem cell transplantation for multiple myeloma. N Engl J Med 349 (2003) 2495-2502
16. Sonneveld P., Van Der Holt B., Segeren C.M., et al. Intensive versus double intensive therapy in untreated multiple myeloma. Updated analysis of the prospective phase III study Hovon 24-MM. Haematologica 90 Suppl 1 (2005) 37-38 [abstract]
17. Cavo M., Zamagni E., Cellini C., et al. Single versus tandem autologous transplants in multiple myeloma: Italian experience. Haematologica 90 Suppl 1 (2005) 39-40 [abstract]
18. Goldschmidt H. Single versus double high dose therapy in multiple myeloma: second analysis of the trial GMMG-HD2. Haematologica 90 Suppl 1 (2005) 38 [abstract]
19. Barlogie B., Tricot G., Rabmussen E., et al. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and post-transplantation consolidation therapies. Blood 107 (2006) 2633-2638
20. Moreau P., Hullin C., Garban F., et al. Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. Blood 107 (2006) 397-403
21. Rajkumar V., Blaad E., Vesole D., et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24 (2006) 431-436
22. Cavo M., Zamagni E., Tosi P., et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 106 (2005) 35-39
23. Goldschmidt H., Sonneveld P., Breitkreuz I., et al. HOVON 50/GMMG-HD3 trial: Phase III study on the effect of thalidomide combined with high-dose melphalan in myeloma patients up to 65 years. Blood 106 (2005) 128 [abstract]
24. Macro M., Divine M., Uzunban Y., et al. Dexamethasone + thalidomide compared to VAD as pre-transplant treatment in newly diagnosed multiple myeloma: a randomized trial. Blood 108 (2006) 22 [abstract]
25. Jagannath S., Durie B., Wolf J., et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 129 (2005) 776-783
26. Oakervee H.E., Pollat R., Curry N., et al. PAD combination therapy (PS341, doxorubicin and dexamethasone) for untreated multiple myeloma. Br J Haematol 29 (2005) 755-762
27. Popat R., Oakervee H.E., Curry N., et al. Reduced dose PAD (PS 341, Adriamycin and dexamethasone) for previously untreated patients with multiple myeloma. Blood 106 (2005) 717 [abstract]
28. Harousseau J.L., and Attal M. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma. Haematologica 91 (2006) 1498-1505
29. Barlogie B., Tricot G., Rasmussen E., et al. Total therapy incorporating Velcade into upfront management of multiple myeloma: comparison with TT2 + Thalidomide. Blood 106 (2005) 337 [abstract]
30. Wang M., Delaballe K., Giralt S., et al. Rapid control of previously untreated multiple myeloma with bortezomib-thalidomide-dexamethasone followed by early intensive therapy. Blood 106 (2005) 231 [abstract]
31. Rajkumar S.V., Hayman S.R., Lacy M.Q., et al. Combination therapy with lenalidomide plus dexamethasone for newly diagnosed myeloma. Blood 106 (2005) 4050-4053
32. Attal M., Harousseau J.L., Leyvras S., et al. Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood 15 (2006) 3289-3294
33. Spencer A., Prince M., Roberts A.W., et al. First analysis of the Australian leukaemia and lymphoma group trial of thalidomide and alternate day prednisone following autologous stem cell transplantation for patients with multiple myeloma. Blood 108 (2006) 22 [abstract]
34. Barlogie B., Tricot G., Anaissie E., et al. Thalidomide and hematopoietic cell transplantation for multiple myeloma. N Engl J Med 354 (2006) 1021-1030
35. Siegel D.S., Desikan K.R., Nehta J., et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 93 (1999) 51-54
36. Badros A., Barlogie B., Siegel E., et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 114 (2001) 600-607
37. Palumbo A., Triolo S., and Argentin C. Dose intensive melphalan with stem-cell support is superior to standard treatment in elderly myeloma patients. Blood 94 (1999) 1248-1253
38. Palumbo A., Bringhen S., Petrucci M.T., et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50-70: results of a randomized controlled trial. Blood 104 (2004) 3052-3057
39. Facon T., Mary J.Y., and Harousseau J.L. Superiority of melphalan and prednisone plus thalidomide over melphalan and prednisone alone or autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. J Clin Oncol 24 (2006) 1s [abstract]
40. Badros A., Barlogie B., Siegel E., et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 114 (2001) 822-829
41. Tosi P., Zamagni E., Ronconi S., et al. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and renal failure. Leukemia 14 (2000) 1310-1313
42. San Miguel J., Lahuerta J.J., Garcia-Sanz R., et al. Are myeloma patients with renal failure candidate for autologous stem cell transplantation. Hematol J 1 (2000) 28-36
43. Vesole D., Tricot G., Jagannath S., et al. Autotransplant in multiple myeloma: what have we learned?. Blood 88 (1996) 838-847
44. Facon T., Avet-Loiseau H., Guillerm G., et al. Chromosome 13 abnormalities identified by Fish analysis and serum b2 microglobulin produce powerful myeloma staging system for patients receiving high-dose therapy. Blood 97 (2001) 1566-1571
45. Tricot G., Spencer T., Sawyer J., et al. Predicting long-term (≥ 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplant. Br J Haematol 116 (2002) 211-217
46. Shaughnessy J., Jacobson J., Sawyer J., et al. Continuous absence of metaphase-defined cytogenetic abnormalities especially of chromosome 13 and hypodiploidy ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. Blood 101 (2003) 3849-3856
47. Fassas A.T., Spencer T., Sawyer J., et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol 118 (2002) 1041-1047
48. Chang H., Sloan S., Li D., et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol 125 (2004) 64-68
49. Gertz M., Lacy M.Q., Dispenzieri A., et al. Clinical implications of t(11;14) (q13;q32), t(4;14) (p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 106 (2005) 2837-2840
50. Jaksic W., Trudel S., Chang H., et al. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. J Clin Oncol 23 (2005) 7069-7073
51. Chang H., Qi C., Yi Q.L., et al. p53 gene deletion detected by fluorescence in situ hybridisation is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 105 (2005) 358-360
52. Avet-Loiseau H., Attal M., Moreau P., et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood 109 (2007) 3489-3495
53. Palumbo A., Bringhen S., Caravita T., et al. Oral Melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367 (2006) 825-831
54. Mateos M.V., Hernandez J.M., Gutierrez W.C., et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase I/II study. Blood 108 (2006) 2165-2172
55. Palumbo A., Falco P., Falcone A., et al. Oral Revlimid plus melphalan and prednisone for newly diagnosed multiple myeloma: results of a multicenter phase I/II study. Blood (2006) [online]
56. Lacy M., Gertz M., Dispenzieri A., et al. Lenalidomide plus dexamethasone in newly diagnosed myeloma: response to therapy, time to progression and survival. Blood 108 (2006) 230 [abstract]
57. Corradini P., Voena C., Tarella C., et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 17 (1999) 208-215
58. Gahrton G., Tura S., Ljungman P., et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 13 (1995) 1312-1322
59. Bensinger W.I., Buckner C.D., Anasetti C., et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 88 (1996) 2787-2793
60. Mehta J, Allogeneic hematopoietic stem cell transplantation in myeloma. In: Myeloma editions J Mehta, S Singhal. Martin Dunitz London 2002; p. 349-65.
61. Bjorkstrand B.B., Ljungman P., Svensson H., et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 88 (1996) 4711-1718
62. Couban S., Stewart A.K., Loach D., et al. Autologous and allogeneic transplantation for multiple myeloma. Bone Marrow Transplant 19 (1997) 783-789
63. Gahrton G., Svensson H., Cavo M., et al. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation Centres. Br J Haematol 113 (2001) 209-216
64. Lokhorst H.M., Segeren C.M., Verdonck L.F., et al. Partially T-cell depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study Hovon 24 MM. J Clin Oncol 21 (2003) 1728-1733
65. Tricot G., Vesole D.H., Jagannath S., et al. Graft-versus myeloma effect: proof of principle. Blood 87 (1996) 1196-1198
66. Verdonck L., Lokhorst H., Dekker A., et al. Graft versus myeloma effect in two cases. Lancet 347 (1996) 800-801
67. Aschan J., Lonnquist B., Ringden O., et al. Graft-versus myeloma effect. Lancet 348 (1996) 346
68. Collins R.H., Shpilberg O., Drobyski W.R., et al. Donor lymphocyte infusions in 140 patients with relapsed malignancies after allogeneic bone marrow transplantation. J Clin Oncol 22 (1997) 835-843
69. Lokhorst H.M., Wu K., Verdonck L.F., et al. The occurrence of graft versus host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 103 (2004) 4362-4364
70. Giralt S., Aleman A., Anagnostopoulos A., et al. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 30 (2002) 367-373
71. Einsele H., Schafer H.J., Hebart H., et al. Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning. Br J Haematol 121 (2003) 411-418
72. Peggs K.S., Mackinnon S., Williams C.D., et al. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus tumor activity. Biol Blood Marrow Transplant 9 (2003) 257-265
73. Perez-Simon J.A., Martino R., Alegre A., et al. Chronic but not acute graft versus host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation. Br J Haematol 121 (2003) 104-108
74. Mohty M., Boiron J.M., Damaj G., et al. Graft-versus myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 34 (2004) 77-87
75. Gerull S., Goerner M., and Benner A. Long-term outcome of non myeloablative allogeneic transplantation in patients with high-risk multiple myeloma. Bone Marrow Transplant 36 (2005) 963-969
76. Kroger N., Sayer H.G., Schwerdtfeger R., et al. Unrelated stem cell transplantation in reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 100 (2002) 3919-3924
77. Crawley C., Lalancette M., Szydlo R., et al. Outcomes of reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 105 (2005) 4532-4539
78. Crawley C., Iacobelli S., Björkstrand B., et al. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 109 (2007) 3588-3594
79. Badros A., Barlogie B., Siegel E., et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after non-myeloablative conditioning. J Clin Oncol 20 (2002) 1295-1303
80. Kroger N., Schwerdtfeger R., Kiehl M., et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 100 (2002) 755-760
81. Maloney D., Molina A., Sahebi F., et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 101 (2003) 3447-3454
82. Garban F., Attal M., Michallet M., et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM 99-03 trial) with tandem autologous stem cell transplantation (IFM 99-04 trial) in high-risk de novo multiple myeloma. Blood 107 (2006) 3474-3480
83. Bruno B., Rotta M., Patriarca F., et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 356 (2007) 1110-1120
84. Moreau P, Garban F, Facon T, et al. Long-term and updated results of the IFM9903 and IFM9904 protocols comparing autologous followed by RIC-allogeneic transplantation and double transplant in high-risk de novo multiple myeloma. Bone Marrow Transplant 39(Suppl 1):S24-5 [abstract].
85. Kroger N., Shimoni A., Zagrivnaja M., et al. Low-dose thalidomide and donor lymphocyte infusions as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood 104 (2004) 3361-3363
86. Bruno B., Patriarca F., Sorasio R., et al. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation. Haematologica 91 (2006) 837-839
87. Tosi P., Zamagni E., Cangini B., et al. Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation. Ann Hematol 85 (2006) 549-558
88. Van de Donk N.W., Kroger N., Hegenbart U., et al. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. Blood 107 (2006) 3415-3416
89. Kroger N., Zabelina T., Ayuk F., et al. Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status. Exp Hematol 34 (2006) 770-775
90. Kroger N., Schilling G., Einsele H., et al. Deletion of chromosome 13q14 detected by fluorescence in situ hibridization as prognostic factor following allogeneic dose-reduced stem cell transplantation in patients with multiple myeloma. Blood 103 (2006) 4056-4061